Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuqin SongMJMing JiangXSXiuhua Sun

Discussion

Loading...

Member takes

Overview

Phase 1 trial demonstrates high response rates and a favorable safety profile for rocbrutinib in BTK inhibitor naïve R/R MCL patients, indicating significant therapeutic potential.

Key Points

  • 89.3% overall response rate observed in patients after median follow-up of 21.2 months, suggesting substantial efficacy.
  • Safety profile remains favorable with no severe treatment-related adverse events or drug discontinuation reported.
  • Phase 1 trial with patients aged 18-80 evaluates efficacy of rocbrutinib monotherapy in relapsed/refractory MCL.
  • Findings underscore the promise of targeted therapy for overcoming resistance in lymphoma treatment.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9dahttps://doi.org/10.1182/blood-2025-3587
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial2025 · 1 citations
  2. 2Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)2025 · 3 citations
  3. 3Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor2025 · 2 citations
  4. 4Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 6 citations
  5. 5Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma2025